Richard S. Lindahl - 12 Feb 2025 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Role
EVP, Chief Financial Officer
Signature
/s/ Richard S. Lindahl
Issuer symbol
EBS
Transactions as of
12 Feb 2025
Net transactions value
-$13,135
Form type
4
Filing time
04 Mar 2025, 16:05:01 UTC
Previous filing
13 Feb 2025
Next filing
10 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EBS Common Stock Disposed to Issuer $0 -16,916 -9.9% $0.000000 154,093 12 Feb 2025 Direct F1
transaction EBS Common Stock Tax liability $8,026 -1,073 -0.7% $7.48 153,020 28 Feb 2025 Direct F2
transaction EBS Common Stock Tax liability $5,109 -683 -0.45% $7.48 152,337 01 Mar 2025 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA margin calculated on a cumulative basis over the three-year period beginning January 1, 2022 and ending December 31, 2024, as certified by the Compensation Committee following the performance period. On February 12, 2025, the final certification date, the Compensation Committee certified the achievement of the 2022-2024 PSUs at a payout factor of 0.00% of target resulting in the actual award of 0 shares of common stock, which is below the 16,916 shares previously reported on March 1, 2022.
F2 Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

Remarks:

This Form 4 was filed late due to an inadvertent administrative error. The Company will report all late Form 4s in its next proxy statement